Amneal Pharmaceuticals reported that the first 111 patients enrolled in its Phase 4 ELEVATE‑PD study achieved clinically meaningful improvements after switching to CREXONT®, the company’s next‑generation extended‑release carbidopa/levodopa formulation. The interim data, presented at the 2026 American Academy of Neurology conference, show a significant increase in daily “Good On” time and a reduction in “Off” time across all prior treatment groups, including patients who had previously used the company’s RYTARY® formulation.
CREXONT® combines immediate‑release granules with extended‑release pellets and a mucoadhesive polymer that adheres to the intestinal mucosa, allowing for a more sustained release of levodopa. The study’s findings—an average gain of 3.07 hours of additional daily “Good On” time and nearly doubled continuous “Good On” intervals for patients switching from RYTARY®—demonstrate that the technology delivers longer, uninterrupted symptom control, a key unmet need in Parkinson’s disease management.
The clinical milestone is strategically important because CREXONT® received FDA approval in August 2024 and has recently expanded insurance coverage to the Veterans Administration, UnitedHealthcare, and CVS Health, covering more than 50 % of insured lives. Amneal’s plan to build a comprehensive evidence base for CREXONT® throughout 2026 positions the drug to capture a growing share of the extended‑release carbidopa/levodopa market and to strengthen the company’s specialty Parkinson’s disease portfolio.
Amneal’s Q4 2025 earnings, released on April 20 2026, surpassed expectations with an adjusted EPS of $0.21 versus the consensus of $0.18 and revenue of $814 million versus the forecast of $806 million. The earnings beat was driven by strong performance in the specialty segment, where CREXONT® and other new products are expected to generate significant revenue. UBS and Truist Securities raised their price targets to $19.00 and $17.00, respectively, citing the projected $440 million in sales for CREXONT® by 2030 and the company’s focus on margin expansion.
Analysts responded positively to the interim results, noting that the data reinforce Amneal’s competitive positioning and support the company’s guidance for continued growth in the specialty Parkinson’s disease market. The favorable clinical outcomes, combined with the company’s recent earnings beat and expanding market access, are expected to enhance investor confidence in Amneal’s long‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.